Клезитамиг

Prop. INN (наименование, предложенное ВОЗ)

2930861-48-4

immunoglobulin [(V-kappa-G4CH1-G1h-H-gamma1_L-kappa)_L-kappa)]_(H-gamma1_L-kappa), anti-[Homo sapiens DLL3 (delta-like ligand 3, delta like canonical Notch ligand 3)], anti-[Homo sapiens CD3/TNFRSF9 (TNF receptor superfamily member 9, 4-1BB, T cell antigen ILA, CD137) dual non simultaneous], humanized monoclonal antibody, trispecific, trivalent;
fused heavy chain V-kappa-G4CH1-G1h anti-DLL3-H-gamma1 anti-CD3/TNFRSF9 (1-676) [V-kappa-G4CH1-G1h anti-DLL3 humanized (1-215) [V-KAPPA (Homo sapiens IGKV1-33*01 (76.3%) -IGKJ4*01 (100%), CDR-IMGT [8.3.10] (27-34.52-54.91-100)) (1-110) -2-mer diseryl (111-112)- Homo sapiens IGHG4*01 G4v97 S10 (CH1 C10>S (126) (113-210) -IGHG1*01 hinge 1-5  (211-215)) (113-215)] -5-mer (tetraglycyl-seryl) linker (216-220) -H-gamma1 heavy chain humanized, anti-CD3/TNFRSF9 (221-676) [VH (Homo sapiens IGHV3-72*01 (78.6%) -(IGHD) -IGHJ6*01 (86.7%), CDR-IMGT [8.10.19] (246-253.271-280.319-337)) (221-348) -Homo sapiens IGHG1*01 G1m17,1 CH1 K120, CH3 D12, L14, G1v57 CH1 E26, E119, G1v94 CH1 C94, G1v14 CH2 A1.3, A1.2, G1v29 CH2 A84.4, G1v74 CH3 C10, G1v32 CH3 W22 (knob), G1v78 CH3 L107, A114, G1v89 CH3 R118, E120 (CH1 K26>E (378), S94>C (422), K119>E (444), K120 (445) (349-446), hinge 1-15 (447-461), CH2 L1.3>A (465), L1.2>A (466), N84.4>A (528) (462-571), CH3 S10>C (585), D12 (587), L14 (589), T22>W (597), M107>L (659), N114>A (665), Q118>R (669), S120>E (671) (572-676)) (349-676)]]; (215-226')-disulfide with the VH-C-kappa light chain anti-DLL3 humanized (1'-226') [VH (Homo sapiens IGHV4-61*02 (72.0%) -IGHD -IGHJ4*01 (86.7%), CDR-IMGT [9.8.11] (26'-34'.52'-59'.98'-108')) (1'-119') -Homo sapiens IGKC*01 (99.1%) Km3 A45.1, V101, KCv96 A1.4, S1.3 (C-KAPPA R1.4>A (120'), T1.3>S (121'), A45.1 (165'), V101 (203')) (120'-226')]; (451-219''')-disulfide with common L-kappa light chain humanized, anti-CD3/TNFRSF9 (1'''-219''') [V-KAPPA (Homo sapiens IGKV2-30*02 (80.0%) -IGKJ2*01 (100%), CDR-IMGT [11.3.9] (27'''-37'''.55'''-57'''.94'''-102''')) (1'''-112''') -Homo sapiens IGKC*01 (98.1%) Km3 A45.1, V101, KCv57 R12, K13 (C-KAPPA E12>R (128'''), Q13>K (129'''), A45.1 (158'''), V101 (196''')) (113'''-219''')];
H-gamma1 heavy chain anti-CD3/TNFRSF9 humanized (1''-456'') [VH (Homo sapiens IGHV3-72*01 (78.6%) -(IGHD) -IGHJ6*01 (86.7%), CDR-IMGT [8.10.19] (26''-33''.51''-60''.99''-117'')) (1''-128'') -Homo sapiens IGHG1*01 G1m17,1 CH1 K120, CH3 D12, L14, G1v57 CH1 E26, E119, G1v94 CH1 C94, G1v14 CH2 A1.3, A1.2, G1v29 CH2 A84.4, G1v75 CH3 C5, G1v33 CH3 S22, A24, V86 (hole), G1v78 CH3 L107, A114, G1v89 R118, E120 (CH1 K26>E (158''), S94>C (202''), K119>E (224''), K120 (225'') (129''-226''), hinge 1-15 (227''-241''), CH2 L1.3>A (245''), L1.2>A (246''), N84.4>A (308'') (242''-351''), CH3 Y5>C (360''), D12 (367''), L14 (369''), T22>S (377''), L24>A (379''), Y86>V (418''), M107>L (439''), N114>A (445''), Q118>R (449''), S120>E (451'') (352''-456'')) (129''-456'')], (231''-219'''')-disulfide with common L-kappa light chain humanized, anti-CD3/TNFRSF9 (1''''-219'''') [V-KAPPA (Homo sapiens IGKV2-30*02 (80.0%) -IGKJ2*01 (100%), CDR-IMGT [11.3.9] (27''''-37''''.55'''-57''''.94''''-102'''')) (1''''-112'''') -Homo sapiens IGKC*01 (98.1%) Km3 A45.1, V101, KCv57 R12, K13 (C-KAPPA E12>R (128''''), Q13>K (129''''), A45.1 (158''''), V101 (196'''')) (113''''-219'''')]; heterodimer (422-202'':457-237'':460-240'':585-360'')-tetrakisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DXB11, non-glycosylated

Поделиться этой страницей